Pfizer Corporation

Michelle Ann Schmidt

Margaret Lanahan Grapperhaus

Balekudru Devadas

Eddine Saiah

Susan Landis Hockerman

Shaun Raj Selness

Mark E Schnute

Li Huang Xing

Robert Owen Hughes

Christoph Wolfgang Zapf

Daniel Patrick Walker

Zhao-Kui Wan

Seungil Han

John Robert Springer

Danny James Garland

Matthew James Graneto

Michael B Tollefson

Mark A Massa

Todd M Maddux

Grace Mary Wagner

Matthew William Mahoney

Edgardo Alvira

Jon Gordon Selbo

Richard Alan Vonder Embse

Kirby Ray Sample

Ronald Edward Seidel

Scott Santford Woodard

Kaliappan Iyanar

Mark Edward Schnute

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I) 

Bruton's tyrosine kinase inhibitors

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseeases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. 

The invention relates to compounds of formula (I) processes for their preparation, their use as 5-lipoxygenase inhibitors and pharmaceutical compositions containing the same.

Pyrazole derivatives as 5-LO-inhibitors

Growing community of inventors

Millstadt, IL, United States of America

Michelle Ann Schmidt